Skip to content
Buy This GLP
← Research
Evidence

Semaglutide Use by Income and Insurance in US Adults With Type 2 Diabetes

In a 2022 U.S. survey, higher income and private insurance were associated with greater odds of semaglutide use among adults with type 2 diabetes.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team5 min read
Adjusted odds of using the drugincome above median1.61private insurance1.521.0US adults with type 2 diabetes, 2022 survey data

Researchers examined semaglutide use in U.S. adults with type 2 diabetes using the 2022 Medical Expenditure Panel Survey (n = 2,542) [1]. Our guide to GLP-1 insurance coverage explains why the covered product and the reason for prescribing matter. This analysis grouped people by income and insurance status.

What were the adjusted differences?

Adults with incomes above the median had higher odds of semaglutide use (OR 1.61, 95% CI 1.14–2.26). Private insurance was also associated with higher odds (OR 1.52, 95% CI 1.04–2.22) [1]. These are adjusted odds ratios. They do not give the absolute difference in the share of people taking semaglutide.

How does this relate to today’s prices?

The survey was cross-sectional and limited to adults with diagnosed type 2 diabetes. The guide to current GLP-1 price ranges explains how to interpret medication and program charges today. The 2022 survey did not measure how those current offers affect access.

Frequently asked

How large was the income association?
The adjusted odds ratio was 1.61, with a 95% confidence interval from 1.14 to 2.26. This estimate concerns odds of use in the study population.
Did the analysis cover semaglutide use for weight loss?
The sample consisted of U.S. adults diagnosed with type 2 diabetes in the 2022 Medical Expenditure Panel Survey.

Sources

  1. [1] Vaidya V, et al. (2026). Income disparities and accessibility to Semaglutide: implications for diabetes management and policy reform International Journal for Quality in Health Care. PMID 41437637

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence